NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/09/2024
Back to search
Official data from USPTO
EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN.
ST13
US500000090459471Class
42
Filing
90459471
Registration
7443900
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
07/09/2024
Trademark type
Word
Nice classes
42
Filing date
01/11/2021
Registration date
07/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/09/2024
Last transaction
07/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2020-08-00
First use in commerce
2020-08-00
Drawing code
4
Owner type
03
Owner location
Seattle, WA, US
Examiner
MICHELI, ANGELA M
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Adaptive Biotechnologies Corp.
Representatives
Hoang-chi Truong Patent Law Works LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of residual diseasethe analysisevaluationreporting of those test results to help healthcare professionals for research purposes; development of new technology for others in the field of biotechnology; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; genome amplification; genotyping services for research or analysis purposes; laboratory research in the field of immune sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immune sequencing; providing laboratory research services in the field of gene expressioncancer biology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; research and development in the pharmaceutical and biotechnology fields; researchdevelopmentengineering and testing services in the fields of immunopharmaceuticals and vaccines; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; medical research; consulting services in the fields of biotechnologypharmaceutical research and development and genetic science; consulting services in the fields of biotechnologypharmaceutical research and developmentlaboratory testingdiagnosticspharmacogenetics; custom design and development of chemical reagents and biochemical assays; development of new technology for others in the field of immunotherapy; laboratory research in the field of immunotherapyoncologyhematologyauto-immune disordersinfectious diseases; medical and scientific research in the field of immunotherapy; medical laboratory services
Publications
History of USPTO decisions and trademark events.
35 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/31/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/31/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/30/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/28/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/30/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/04/2023
EX4G
SOU EXTENSION 4 GRANTED
11/02/2023
EXT4
SOU EXTENSION 4 FILED
11/02/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/02/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/03/2023
EX3G
SOU EXTENSION 3 GRANTED
05/01/2023
EXT3
SOU EXTENSION 3 FILED
05/01/2023
EEXT
SOU TEAS EXTENSION RECEIVED
05/01/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/04/2022
EX2G
SOU EXTENSION 2 GRANTED
11/02/2022
EXT2
SOU EXTENSION 2 FILED
11/02/2022
EEXT
SOU TEAS EXTENSION RECEIVED
11/02/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2022
EX1G
SOU EXTENSION 1 GRANTED
05/02/2022
EXT1
SOU EXTENSION 1 FILED
05/02/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/02/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/07/2021
PUBO
PUBLISHED FOR OPPOSITION
09/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/18/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
07/28/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/28/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
07/28/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/28/2021
DOCK
ASSIGNED TO EXAMINER
07/20/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/11/2021
NWAP
NEW APPLICATION ENTERED
01/14/2021
Continuous trademark protection
Get notified about every new filing that threatens EVERY IMMUNE SYSTEM HAS A STORY TO TELL. THE KEY IS KNOWING HOW TO LISTEN. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.